-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 KilzgIZJTcrL+LLARWnjGcPM9EQ71kBDF65Mi8BW/+zQN0yQQPS5OppC/PdZvW9M
 +EhYrC5JxNZaDQobzE9smQ==

<SEC-DOCUMENT>0000950133-04-004738.txt : 20041223
<SEC-HEADER>0000950133-04-004738.hdr.sgml : 20041223
<ACCEPTANCE-DATETIME>20041223111427
ACCESSION NUMBER:		0000950133-04-004738
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20041221
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041223
DATE AS OF CHANGE:		20041223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HUMAN GENOME SCIENCES INC
		CENTRAL INDEX KEY:			0000901219
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				223178468
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14169
		FILM NUMBER:		041222847

	BUSINESS ADDRESS:	
		STREET 1:		14200 SHADY GROVE ROAD
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850-3338
		BUSINESS PHONE:		3013098504

	MAIL ADDRESS:	
		STREET 1:		14200 SHADY GROVE ROAD
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>w04123e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">







<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>


<P align="center" style="font-size: 10pt"><HR size="1" noshade width="25%" align="center">


<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B>


<P align="left" style="font-size: 10pt">Date of Report (Date of earliest event reported): <B>December&nbsp;21, 2004</B>


<P align="center" style="font-size: 24pt"><B>HUMAN GENOME SCIENCES, INC.</B>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B><BR>
(State or other jurisdiction<BR>
of incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>0-022962</B><BR>
(Commission<BR>
File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>22-3178468</B><BR>
(IRS Employer<BR>
Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><B>14200 Shady Grove Road, Rockville, Maryland 20850-7464</B><BR>
(Address of principal executive offices)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ZIP Code)



<P align="left" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(301)&nbsp;309-8504</B>

<br>
<br>
<br>
<br>



<HR size="1" noshade width="100%" align="left">

<DIV align="center" style="font-size: 10pt">(Former name or former address, if changed since last report.)</DIV>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:

<P align="left" style="font-size: 10pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)

<P align="left" style="font-size: 10pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)

<P align="left" style="font-size: 10pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

<P align="left" style="font-size: 10pt"><FONT face="Wingdings">&#111;</FONT>&nbsp;Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">








<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt"><B>Section&nbsp;1 &#151; Registrant&#146;s Business and Operations</B>


<P align="left" style="font-size: 10pt">Item&nbsp;1.01. Entry into a Material Definitive Agreement.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;21, 2004, Human Genome Sciences, Inc. (the &#147;Company&#148;) entered into Executive
Agreements with Steven C. Mayer, James H. Davis, Ph.D., David C. Stump, M.D. and Susan Bateson
McKay (each, an &#147;Executive&#148;). Each Executive Agreement provides that in the event the respective
Executive&#146;s employment is terminated by the Company without cause or terminated by the Executive
for cause, the Company shall pay to the Executive all accrued but unpaid base salary, any earned
but unpaid bonuses for any prior period, all earned or vested incentive compensation, deferred
compensation and other compensation or benefits, all accrued but unpaid reimbursable business
expenses and all accrued but unused vacation time. The Company shall continue to pay the
Executive&#146;s base salary for a period of 12&nbsp;months and the Company shall also pay to the Executive a
pro-rata bonus payment based on the bonus earned the prior fiscal year. The Executive will be
entitled to continue to participate in the Company&#146;s group medical, dental, life and disability
programs for a period of 12&nbsp;months at the Company&#146;s sole expense; provided that the Executive is
not then eligible to participate in a group health plan of another entity. The Executive shall
have 12&nbsp;months from the date of his or her termination to exercise all vested stock options
outstanding upon the date of termination, but in no event may the Executive or his or her estate
exercise any stock option beyond its term stated in the applicable award agreement.


<P align="left" style="font-size: 10pt">Item&nbsp;1.02. Termination of a Material Definitive Agreement.



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;22, 2004, the Company entered into an agreement under which the Company will exit
the facility at 9800 Medical Center Drive as part of its previously disclosed plan to consolidate
its operations into fewer locations. The party holding title to 9800 Medical Center Drive has
entered into a new lease with an undisclosed third party. The transaction will free up $76&nbsp;million
of cash by eliminating the cash restriction associated with the financing of 9800 Medical Center
Drive. The transaction reduces the total amount of cash restricted on the Company&#146;s balance sheet,
which is related to various facility financings, from $294&nbsp;million to $218&nbsp;million. The Company
will sublease a portion of the space at 9800 Medical Center Drive back from the assignee for up to
two years.


<P align="left" style="font-size: 10pt"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits</B>



<P align="left" style="font-size: 10pt">Item&nbsp;9.01. Financial Statements and Exhibits.



<P align="left" style="font-size: 10pt">(c)&nbsp;Exhibits.



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1 Press Release dated December&nbsp;22, 2004.


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 10pt">SIGNATURES


<P align="left" style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">HUMAN GENOME SCIENCES, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ James H. Davis, Ph.D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD colspan="2" align="left">James H. Davis, Ph.D.&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD colspan="2" align="left">Executive Vice President, General Counsel<BR>
and Secretary&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Date: December&nbsp;23, 2004




<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 10pt"><B>INDEX TO EXHIBITS</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit No.</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Description</B><HR size="1" noshade></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release dated December&nbsp;22, 2004.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>w04123exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="right" style="font-size: 10pt">Exhibit 99.1

<P align="left" style="font-size: 10pt"><IMG src="w04123hgs.gif" alt="(HUMAN GENOME SCIENCES, INC. LOGO)">



<P align="left" style="font-size: 10pt"><B>FOR IMMEDIATE RELEASE</B>


<P align="left" style="font-size: 10pt"><B>CONTACTS:</B><BR>
Steven C. Mayer<BR>
Executive Vice President &#038; Chief Financial Officer<BR>
240/314-4400<BR>
Jerry Parrott<BR>
Vice President, Corporate Communications<BR>
301/315-2777<BR>
Kate de Santis<BR>
Director, Investor Relations<BR>
301/251-6003


<P align="center" style="font-size: 10pt"><B>HUMAN GENOME SCIENCES ANNOUNCES AGREEMENT TO EXIT FACILITY AT<BR>
9800 MEDICAL CENTER DRIVE</B>



<P align="center" style="font-size: 10pt"><I>- Action Will Make $76 Million in Additional Cash Available on Balance Sheet -</I>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ROCKVILLE, Maryland &#151; December&nbsp;22, 2004 &#151; Human Genome Sciences, Inc. (Nasdaq: HGSI)
announced today that it has completed an agreement under which the company will exit the facility
at 9800 Medical Center Drive as part of its previously disclosed plan to consolidate its operations
into fewer locations.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maryland Economic Development Corporation (MEDCO)&nbsp;will continue to hold title to the facility,
which has served as Human Genome Sciences&#146; research center, and has entered into a new lease with
an undisclosed third party.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Steven C. Mayer, Executive Vice President and Chief Financial Officer, said, &#147;The agreement
announced today is an important component of our previously disclosed facilities consolidation
program. It will also free up $76&nbsp;million of cash by eliminating the cash restriction associated
with the financing of 9800 Medical Center Drive. This transaction reduces the total amount of cash
restricted on our balance sheet, which is related to various facility financings, from $294&nbsp;million
to $218&nbsp;million. Most of our employees who are currently working there will be moved to other
Human Genome Sciences locations in Rockville, including our newest facility at 14200 Shady Grove
Road. We will continue to use a portion of the 9800 building for a
period of time, so certain employees will remain there for now and be moved to our other facilities at a later
date.&#148;



<P align="center" style="font-size: 10pt">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This announcement contains forward-looking statements within the meaning of Section&nbsp;27A of the
Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as
amended. The forward-looking statements are based on Human Genome Sciences&#146; current intent, belief
and expectations. These statements are not guarantees of future performance and are subject to
certain risks and uncertainties that are difficult to predict. Actual results may differ
materially from these forward-looking statements because of the Company&#146;s unproven business model,
its dependence on new technologies, the uncertainty and timing of clinical trials, the Company&#146;s
ability to develop and commercialize products, its dependence on collaborators for services and
revenue, its substantial indebtedness and lease obligations, its changing requirements and costs
associated with planned facilities, intense competition, the uncertainty of patent and intellectual
property protection, the Company&#146;s dependence on key management and key suppliers, the uncertainty
of regulation of products, the impact of future alliances or transactions and other risks described
in the Company&#146;s filings with the Securities and Exchange Commission. Existing and prospective
investors are cautioned not to place undue reliance on these forward-looking statements, which
speak only as of today&#146;s date. Human Genome Sciences undertakes no obligation to update or revise
the information contained in this announcement whether as a result of new information, future
events or circumstances or otherwise.


<P align="center" style="font-size: 10pt">###




<P align="center" style="font-size: 10pt">2
</DIV>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>w04123hgs.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 w04123hgs.gif
M1TE&.#=AA`*-`/<``````(````"``("`````@(``@`"`@,#`P,#<P*;*\$`@
M`&`@`(`@`*`@`,`@`.`@``!``"!``$!``&!``(!``*!``,!``.!```!@`"!@
M`$!@`&!@`(!@`*!@`,!@`.!@``"``""``$"``&"``("``*"``,"``."```"@
M`""@`$"@`&"@`("@`*"@`,"@`."@``#``"#``$#``&#``(#``*#``,#``.#`
M``#@`"#@`$#@`&#@`(#@`*#@`,#@`.#@````0"``0$``0&``0(``0*``0,``
M0.``0``@0"`@0$`@0&`@0(`@0*`@0,`@0.`@0`!`0"!`0$!`0&!`0(!`0*!`
M0,!`0.!`0`!@0"!@0$!@0&!@0(!@0*!@0,!@0.!@0`"`0""`0$"`0&"`0("`
M0*"`0,"`0."`0`"@0""@0$"@0&"@0("@0*"@0,"@0."@0`#`0"#`0$#`0&#`
M0(#`0*#`0,#`0.#`0`#@0"#@0$#@0&#@0(#@0*#@0,#@0.#@0```@"``@$``
M@&``@(``@*``@,``@.``@``@@"`@@$`@@&`@@(`@@*`@@,`@@.`@@`!`@"!`
M@$!`@&!`@(!`@*!`@,!`@.!`@`!@@"!@@$!@@&!@@(!@@*!@@,!@@.!@@`"`
M@""`@$"`@&"`@("`@*"`@,"`@."`@`"@@""@@$"@@&"@@("@@*"@@,"@@."@
M@`#`@"#`@$#`@&#`@(#`@*#`@,#`@.#`@`#@@"#@@$#@@&#@@(#@@*#@@,#@
M@.#@@```P"``P$``P&``P(``P*``P,``P.``P``@P"`@P$`@P&`@P(`@P*`@
MP,`@P.`@P`!`P"!`P$!`P&!`P(!`P*!`P,!`P.!`P`!@P"!@P$!@P&!@P(!@
MP*!@P,!@P.!@P`"`P""`P$"`P&"`P("`P*"`P,"`P."`P`"@P""@P$"@P&"@
MP("@P*"@P,"@P."@P`#`P"#`P$#`P&#`P(#`P*#`P/_[\*"@I("`@/\```#_
M`/__````__\`_P#______R'Y!```````+`````"$`HT```BO`/\)'$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7
M,&/*G$FSILV;.'/JW,FSI\^?0(,*'4JTJ-&C2),J7<JTJ=.G4*-*G4JUJM6K
M6+-JW<JUJ]>O8,.*'4NVK-FS:-.J7<NVK=NW<./*G4NWKMV[>//JW<NWK]^_
M@`,+'DRXL.'#B!,K7LRXL>/'D"-+GDRYLN7+F#-KWO_,N;/GSZ!#BQY-NK3I
MTZA3JU[-6B:`U[!CRYY-N[;MV[ASZ][-N[?OW\"#"Q].O+CQX\B3*U_.''E>
M`*VC1X>.E[KTZZBMV]6.O;MH[G3!>Q_/6;Q<\U!G"]3]#W=!]>\-QB8H6^'\
M]NMMMX=-__Y`__D!N-]N",TGWGW0^3:@=O7U]]IZ"\*W('X+N?>?@`@^AAY$
M!R1P#RGSV#,/*0B(>$])]OR3X@'SG#ABB",F\$\"]J2XT8;I/7@A@SK^YR!W
M`EYX$'_TV=<CD0$*F621_37YXWM(#J@DE-3UN*245V*YWX[Q.<CEE3H2::61
M/`))Y9>-X?C0A_,@<,\V'9+_<B)*!VQS(IOVO(G`/R1ZI*93408Z9IE`1HGF
MDSX6.&B93$Z8:):"+FIEH$,>Z:636F9J'8",8DJIEG]J^FF66SH6ZD(O(C!B
MG'-Z9*.*!!T@YS\?WI/`JGRVRM&I2T5ZZ:/X(9G@F`&"QVE"Q%*X9*&38CIE
ML);ZJJQ\EC[[J+3,,NCLM6'^&FJDVEH+H:D8(0`B`MZ0TJ$W\XCTJCT'()"`
M-G=JT^8VI-"H+JRO9L2K4M*2JJVPF4)H*+2;*JJFF/$13"JH$&.+[,$'G_FE
MF0X73&V5B#Y$:<850_8O0O?D*<\!+.J*4+\5O9E``IJX*"<"^";@ILJ[:G7;
MK^.._\M?E<0.:^RR"C,DH<_=/NSPSY`VJ/"DR?)\-(4,/TREH4X;W2R6FT:M
M8;FKWHKS1OW>,P_*(-)*2K[X[FGG0"FRC-'(2`5<<+A,WWTHU7EOK#7'3!JX
M-\12`MWIPL)ZW33@B0IN]:4'ANQWXWU+3JY%]IA[]JRN$K3B-@@<0*^;VN2[
M]@%\MCL2W4?9C77@#QK>I=Y)FI=X@U5SF^#@2\>^>,]DRDXFY+-7KCC73S<T
MJO&L#]8\W"BW*%*)`MUCZYO7QTPSB0EP+E#<?NH,=:?`=FW^U<?NB)ZD4I<O
M*+6-WMZ^?)`?[[K[1]J_-?G#XW^^9<\;2)U4UQ$;=2A%9CQ+0)WR]:9[D<@>
M:9.;W"X2P*&X;E#QRU^X#L6LB?%O>1;[G>XXN+79@2IH)-Q@!WG'0>"):7TE
M%"'L*GC_GHO4"$2H*Z``!<(B>Z2+@3-K6_=F41#PA2\K=B.<^UK8L14638;5
MVAO43*A!;T7.6J,25=>`=;<8)BX_4PI9%KNHPN/]I8*9JUE&4J3`/<GJ'RR2
MEYP4*"<1<6]$</M>'CM"PY_`YVA9PUVQ:*,^0HIK8^,C9"`C)ZFD*8A^01ID
M(7,3H6U)<I""Y%30+`1&1/+/,#3\D#SV-!$;V<A-J+O5C/(EJU%VKUUU0AWG
M)CC!N9'',WW<3`418"_KU6@A1GQ5Z/YA+M35*46L3%OW2`''?=UC3^^"E32/
M>$O-Y%*7-I05B.`T38-$4X#M0B4<YX2Z=VRC3:^$(S=)J4<]_YJRG1JY9C7]
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MJH5N=/M8W91(*$S7!2]K@1:2AV9472_ZD#%A:K8]$=1Z/'RK7`^KDEQN=EGA
M)6\GCQO%[E;J7ZI=B?PP^Z<!8Y=7SWW<=K.U*^WV;R;B55*$]ZNH3L[5J#:Z
MU5+/"<>`C@@!FD.@ZCQJU83"=64HOA$?-\EB_`K-:B!S,,^B.R0!5Y'`VTVN
M0_P[.1XW+%HR?C`%@VR2!!<.N8YRL7/7>-9M[BD!@_T0C5HDXI#6\J>_3?%B
M_85!BDWX9Q/_?NR9P%6H(X/96(HSD/G6_&(%&]BQ/RIS==^<9/4IN3Z&-+*"
M?YPP,CM6D;'3H'C;+"0?6_;+@TXTHNDZK5(*LTY/[I.4:58RM0E4H5GFIW=7
MC+=-7BS0UT7?DY#\101%<<:>U.^-E17H)P:XN&$&=8'#O%\>@3%WA#-RJ0M<
M.S`)3SV]4_6@3UCGFMQXN)/\-9&-AF%8'32!_[AM!"6:LFC/B7H2E"],Y!EC
M)R98S__]'ZD7S27;Z6]87(MU[9(U6ETK.]0>]/*[;^T[;RDYW81&5J^)C6_C
MUCO=]W8WH^=V;$&C&=1[!JX-O]?6B=8,@NA<V^;:]2$5^3.H^TS(E#?+R^ED
MV_K3;<ZLJ>$]<E_O[K_)UJ+)63U:,ULLN_/^&QGO/<DQ@]S%K94=O!V5798S
MN-]`M\GXB%9L>N\\GD:MWIUL^\QEKA*':?O0GNY!1)JQ$^.:;DBF=]QQ3.;O
MY0C7V+0$7FARV[G"5CQ<%?_G6943F^PR=SNX75[NFP==>6AZW]R3O.N8[STF
M[#NRCD.^[`K_+3RG:G/OOLZ5)WL-$%[SD)%&K;[*C&\<M5T/X=AK+6';6??.
M9M]SP+`U=!W;/>!A=W?;24]R\&H>[J^N\<K7O7/6`QWNQH8=Y]?=)=<O.9MJ
MDYD<^Y1/$$$>M@(]4??<*,VMGX3;[#;X%F&M7_A9F.Q]G^*#Z>Q[*2:-N=I?
M^]?QS%^V^YMXX+;]"3DF1D^)_^BE/S/-93UPTCK-]U_G>><Y7A%3LHE/ZN)T
M`A$Z+-(NW2-Y'I4VLN)&[7)0VO:`)&%?4S-=X")F-39>9Z9SXX=F"T8H/V="
M9Q=GPP9GY;:!O/-'R/98Y.=%!`)G\N9(*"@T]V5PM+>"6U1XS@5(_WY62!9X
M89@#<6YR3GFR+R:F@)%'*SN%1]US(E$&4R:F$,['67=1?TE!A2]AA;)'&A7$
M(G3T3"/2*K441[2R#1:G4W=2(N=4(C05A?P7%WUS%EB(><_W;Z/Q/"E2(@TT
MA%?'+^U$2O#E)K!D6\PT:2,">8`W%ZWE%7'($HM(@EJ8$>=D*Z0P6$^84'NB
M*B<":=&F+I.H3B5#4P<`+\V'=;]W'HU85S@8&78(@&UR+B865^TDBF*X-E,F
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MF9:),803QX=8!Y59UX_IPE(N52<QDRIJF9>842.S)2<2%9=@B1$'(`]?)0MF
MLPUP,EM9J9>,__D8LC(+?7DR<-*3)0%BI?,FD=B7B]F8G*D8?(4O2*57Z@@2
M@#@B8J69!-29JID8.84O!9F9)>:,&O%*LB)1L[6:N&D8<?,B?=DB5NDF,D)?
MLBD1266:WIB:N9F<@5&<5ODFL04B"D2*(7$V=9*8&:F<V'D7X#,B?HE#I1,G
M`;42`S2/V5F>?6$/KY1/17DR;W*0OO417O@VYCF?VLE#JW(/W_DB=A1Y9H.6
M+=,G]!F@<A%-(#);LS"4.?6<+S,V(J$O`OJ@<?$N'<(F815YM/AX`W02X0FA
M'-H6PO2<236)=/2-:=,B[AD2F]FA*@H6):4JL>5**+F,$1<B;H6BR+2YHCCZ
M%9>'A!HV?+;XHVG(DRI)$33#43EZI&31+XT7+P(ID.=RC`6E91%A1RF*I%8J
M%4JJ;:@C1#'R2D5Z(LH409#(/5=:IF*1I;1(FXHI6,PD(DF(,@S:$#5#GF9:
MIU21CGLDBN8".IK87@"X2J@34%6:$%*G80UIIXC:%+L81S0UE8IW5D^V7M)9
M$.=BD2^3J)C*HM5VCFLS3H&X2CAUH]Z$G[)TH'G"6?IQ6>AS:CP(/)G_BJA9
M"H$B57%LQ4R`J$X6*GD<]4P)T38`:#,$)1'")48[F';V^*I+Z9\'H4\:=2O&
M%*B5IE%FDU1SPE82Z8J%6!'#&GW<JGEBAZS@.JD%@3(=E4H-2(:"Y2)VXJ6"
M-0NR])%B:G_<>G`PU%@6%JYFNJ/#23*1AC9EV$P6J@U[$B.U*A!AJJT5DUJ2
MDTA9B*\.*ZL*`5.J$W7RB)*HHR=_JCD;!5P)"W.&UZJ-\K`B2Q$V8VEN*BOT
M8E!+IR+I(A`;>F",Y(&FU7(C6[,6@4/)"*C-=+$'959#-J]QAJKW9;-$&Q',
M*J@:Q871AJXX1'#L`;+*1;-%*Z`LHZP-H4]B_^BLT7:$@$53P2JO,1NT,&MH
M4YN;5OL0.>0A/-16E098?BE6UQFU80NUFK6M9%NV]'FVU4-63\:KS>A/D?B=
MF@BVX2:VGL1%FH6WBCM6:\514#9U995#9BEQ846NA(M(/=A8,7NLBNN+5OLJ
MEMLA?'*)?JLZEGN,VU"5]**U,%NXAJNY<]NY5/N0`Z&V&PM'@4I*!W4K,N4Y
MW!E6254Z<?LWL1N"L.NZLHNOB-=1;M20:[4O/30CURDO;W*@E'NYF>N(CBAO
MR8NI<N,FW^-6)4LK+OMDIENEFI-3]F*[PMJQY?>!=7:WW:N6Q.A-@R4K,D)Y
MH9N['1:%T(DK,UL;=3#KOD/+9IP[OW:59;L;4)0WOJ%[:1(!8LDHJ@A<P>[R
MKQYBKIFH.A8U8A4A-K=IP2+_["YNE38:NX2X.X`C-KP<XI0C_,(0P5NJDHL`
MVV'*ISH?!4<L#!&J0HDP_,,Q')2#E8SXA)Y*V"HC=JCW]+5`W,0<PJO)6+#I
MQ+M[&Q+XY,18[!`L<K%-UZGI%+W$-!+-F,5D'%/E*EAG0Y(6QTPL<A+'2"-E
M',<`V8#J4J1JR$Q0=A)QU#URW,=,E:'JM8FU:!)::WQ]C,4(-%7M8B=[DBXT
MPJLEH;3*=,A9K$^WXEX>!E,[S!&\&V(61<D_G"<XQ50S8VTJ@7@VM7R@#,3H
MV6&8[+)QBJ*H,\-(N,FKK+C@8[OL`E&GG+\+G$JW_,,S-2?]J1+0=%!;;%#!
M#,/D.$1.1KH2O*JU?+S,(YQ#ITO!*M&LL4S-R9LY/#2H*-$G'F++W#RU-4)*
M;2P3T`3)Y6S!!@3.[1S/)A<QOO)<SQSAS?:<SVM$SOK<SZ/ISP`=T`(]T`1=
+T`9]T`BM$@$!`#L_
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
